Ogenix Awarded GSA Schedule for EPIFLO Product Line

PR Log (Press Release) – Aug 09, 2009 – Ogenix, a medical technology company, announced today that it has been awarded a GSA Schedule (FSS contract) effective August 1, 2009 for its EPIFLO® product line, allowing doctors to treat chronic wounds using a continuous stream of oxygen on a 24/7 basis.  This contract allows government organizations, particularly VA hospitals and military facilities to more easily acquire EPIFLO units for treatment of chronic and difficult to heal wounds.

EPIFLO, a 3 ounce portable device which stays with the patient during wound treatment, has demonstrated the ability to effectively heal diffucult wounds such as diabetic ulcers, venous stasis and decubitus ulcers (pressure sores) by delivering oxygen to the wound bed around the clock, resulting in closure of many wounds that have previously failed standard wound care as well as more widely used advanced therapies.

"In the past, our wound healing technology and products were primarily available to private pay customers and patients themselves," said Sarang Sarangapani, President of Ogenix.  "With this schedule, all veterans and patients who are treated at a VA hospital can now receive treatment of their wounds with EPIFLO."

GSA Schedules allow government purchases using commercial buying practices to purchase high-quality products at volume discount pricing on a direct-delivery basis. Other benefits of GSA Schedules include shorter lead-times, lower administrative costs and reduced inventories.

Ogenix is a developer, manufacturer, and marketer of small, portable oxygen generation devices used in wound care.  Its EPIFLO products are particularly effective on difficult to heal wounds such as diabetic ulcers, venous stasis and pressure sores.  For additional information, please refer to their website at http://www.ogenix.com .